A review of radiation countermeasure work ongoing at the Armed Forces Radiobiology Research Institute

International Journal of Radiation Biology

Volumn 88, Issue 4, 2012, Pages 296-310

  Singh, Vijay K ^a,b   Ducey, Elizabeth J ^a   Brown, Darren S ^a   Whitnall, Mark H ^a  

^a ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

cytokines; growth factors; radiation; Radiation accidents; radioprotectors

Indexed keywords

ALPHA TOCOPHEROL DERIVATIVE; ALPHA TOCOPHEROL SUCCINATE; ALXN 4100TPO; AMIFOSTINE; ANDROSTENEDIOL; BIO 300; CBLB 502; CBLB 601; CBLB 612; CBLB 613; CLT 008; EX RAD; FIBROBLAST GROWTH FACTOR; FLAGELLIN; FLAVONOID; FLT3 LIGAND; GENISTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; KERATINOCYTE GROWTH FACTOR; MERCAPTAMINE; NEUMUNE; ORIENTIN; PLERIXAFOR; RADIOPROTECTIVE AGENT; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE RADIATION SYNDROME; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; CYTOPENIA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GAMMA IRRADIATION; HEALTH CARE ORGANIZATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IN VIVO STUDY; IONIZING RADIATION; LOW DRUG DOSE; MILITARY RESEARCH; MONOCYTOPENIA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PROTECTION; RADIOBIOLOGY; REVIEW; SINGLE DRUG DOSE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ACADEMIES AND INSTITUTES; ANIMALS; HUMANS; MILITARY MEDICINE; MILITARY PERSONNEL; RADIATION INJURIES; RADIATION PROTECTION; RADIOBIOLOGY;

ANIMALIA;

EID: 84859359102     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2012.652726     Document Type: Review

References (185)

1. Agarwal SS, Singh VK. 1999. Immunomodulators: A review of studies on Indian medicinal plants and synthetic peptides: Part I: Medicinal plants. Proceedings of the Indian National Science Academy B 65:179-2004.
2. Albanese J, Dainiak N. 2003. Modulation of intercellular communication mediated at the cell surface and on extracellular, plasma membrane-derived vesicles by ionizing radiation. Experimental Hematology 31:455-464.
3. Ara G, Watkins BA, Zhong H, Hawthorne TR, Karkaria CE, Sonis ST, Larochelle WJ. 2008. Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. International Journal of Radiation Biology 84:401-412.
4. Arora R, Gupta D, Chawla R, Sagar R, Sharma A, Kumar R, Prasad J, Singh S, Samanta N, Sharma RK. 2005. Radioprotection by plant products: Present status and future prospects. Phytotherapy Research 19:1-22.
5. Augustine AD, Gondre-Lewis T, McBride W, Miller L, Pellmar TC, Rockwell S. 2005. Animal models for radiation injury, protection and therapy. Radiation Research 164:100-109.
6. Beenken A, Mohammadi M. 2009. The FGF family: Biology, pathophysiology and therapy. Nature Reviews Drug Discovery 8:235-253.
7. Ben-Nathan D, Padgett DA, Loria RM. 1999. Androstenediol and dehydroepiandrosterone protect mice against lethal bacterial infections and lipopolysaccharide toxicity. Journal of Medical Microbiology 48:425-4231.
8. Berbee M, Fu Q, Boerma M, Wang J, Kumar KS, Hauer-Jensen M. 2009. gamma-Tocotrienol ameliorates intestinal radiation injury and reduces vascular oxidative stress after total-body irradiation by an HMG-CoA reductase-dependent mechanism. Radiation Research 171:596-605.
9. Berbee M, Fu Q, Garg S, Kulkarni S, Kumar KS, Hauer-Jensen M. 2011. Pentoxifylline enhances the radioprotective properties of gammatocotrienol: Differential effects on the hematopoietic, gastrointestinal and vascular systems. Radiation Research 175:297-306.
10. Blijlevens N, Sonis S. 2007. Palifermin (recombinant keratinocyte growth factor-1): A pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Annals of Oncology 18:817-826.
11. Bruno B, Nash RA, Wallace PM, Gass MJ, Thompson J, Storb R, McSweeney PA. 1999. CD34 + selected bone marrow grafts are radioprotective and establish mixed chimerism in dogs given high dose total body irradiation. Transplantation 68:338-344.
12. Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, Kurnasov OV, Fort FL, Osterman AL, Didonato JA, Feinstein E, Gudkov AV. 2008. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320:226-230.
13. Buwitt-Beckmann U, Heine H, Wiesmuller KH, Jung G, Brock R, Akira S, Ulmer AJ. 2005. Toll-like receptor 6-independent signaling by diacylated lipopeptides. European Journal of Immunology 35:282-289.
14. Carmody RJ, Chen YH. 2007. Nuclear factor-kappaB: Activation and regulation during toll-like receptor signaling. Cellular, Molecular Immunology 4:31-41.
15. Carter AB, May MM, Perry WJ. 2007. The day after: Action following a nuclear blast in a U.S. city. Washington Quarterly 30:19-32.
16. Cellerant Therapeutics. Available at: http://www.cellerant.com/index. html. Accessed 20 January 2011.
17. Chen B, Thomsen SL, Thomas RJ, Oliver J, Welch AJ. 2008. Histological and modeling study of skin thermal injury to 2.0 microm laser irradiation. Lasers in Surgery and Medicine 40:358-370.
18. Chen T, Burke KA, Zhan Y, Wang X, Shibata D, Zhao Y. 2007. IL-12 facilitates both the recovery of endogenous hematopoiesis and the engraftment of stem cells after ionizing radiation. Experimental Hematology 35:203-213.
19. Ciurea SO, Hoffman R. 2007. Cytokines for the treatment of thrombocytopenia. Seminars in Hematology 44:166-182.
20. Cleveland BioLabs, I. Available at: http://www.cbiolabs.com/. Accessed 11 January 2011.
21. Cleveland BioLabs, I. Available at: http://www.cbiolabs.com/. Accessed May 2010.
22. Cleveland BioLabs Inc. Shakhov A, Gudkov A. 2006. Methods of protecting against apoptosis using lipopeptides, WO/2006/138238.
23. Cleveland Clinic Foundation Gudkov AV. 2005. Methods of protecting against radiation using inducers of NF-κB, WO/2005/056055.
24. Cleveland Clinic Foundation Gudkov AV, Didonato JA, Krivokrysenko V. 2007. Flagellin related polypeptide and uses thereof, WO/2006/069198.
25. Coleman CN, Blakely WF, Fike JR, MacVittie TJ, Metting NF, Mitchell JB, Moulder JE, Preston RJ, Seed TM, Stone HB, Tofilon PJ, Wong RS. 2003. Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: Report of a workshop at Bethesda, Maryland, December 17-18, 2001. Radiation Research 159:812-834.
26. Culy CR & Spencer CM. 2001. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61:641-684.
27. Dainiak N. 2010. Rationale and recommendations for treatment of radiation injury with cytokines. Health Physics 98:838-842.
28. Dainiak N, Waselenko JK, Armitage JO, MacVittie TJ, Farese AM. 2003. The hematologist and radiation casualties. Hematology - the American Society of Hematology Education Program: 473-496.
29. Davis TA, Clarke TK, Mog SR, Landauer MR. 2007. Subcutaneous administration of genistein prior to lethal irradiation supports multilineage, hematopoietic progenitor cell recovery and survival. International Journal of Radiation Biology 83:141-151.
30. Davis TA, Mungunsukh O, Zins S, Day RM, Landauer MR. 2008. Genistein induces radioprotection by hematopoietic stem cell quiescence. International Journal of Radiation Biology 84:713-726.
31. Day RM, Barshishat-Kupper M, Mog SR, McCart EA, Prasanna PG, Davis TA, Landauer MR. 2008. Genistein protects against biomarkers of delayed lung sequelae in mice surviving high-dose total body irradiation. Journal of Radiation Research 49:361-372.
32. Deeg HJ, Storb R, Longton G, Graham TC, Shulman HM, Appelbaum F, Thomas ED. 1988. Single dose or fractionated total body irradiation and autologous marrow transplantation in dogs: Effects of exposure rate, fraction size, and fractionation interval on acute and delayed toxicity. International Journal of Radiation Oncology, Biology, Physics 15:647-653.
33. Ding Y, Rotta M, Graves SS, Storer BE, Peterson LJ, Sale GE, Forough R, Zellmer E, Georges GE, Sandmaier BM, Kuhr CS, Storb R. 2009. Delaying DLA-haploidentical hematopoietic cell transplantation after total body irradiation. Biology of Blood and Marrow Transplantation 15:1244-1250.
34. Dorr W, Noack R, Spekl K, Farrell CL. 2001. Modification of oral mucositis by keratinocyte growth factor: Single radiation exposure. International Journal of Radiation Biology 77:341-347.
35. Drouet M, Delaunay C, Grenier N, Garrigou P, Mayol JF, Herodin F. 2008. Cytokines in combination to treat radiation-induced myelosuppression: Evaluation of SCF + glycosylated EPO + pegylated G-CSF as an emergency treatment in highly irradiated monkeys. Haematologica 93:465-466.
36. Drouet M, Herodin F. 2010. Radiation victim management and the haematologist in the future: Time to revisit therapeutic guidelines? International Journal of Radiation Biology 86:636-648.
37. Drouet M, Mourcin F, Grenier N, Delaunay C, Mayol JF, Lataillade JJ, Peinnequin A, Herodin F. 2005. Mesenchymal stem cells rescue CD34 + cells from radiation-induced apoptosis and sustain hematopoietic reconstitution after coculture and cografting in lethally irradiated baboons: Is autologous stem cell therapy in nuclear accident settings hype or reality? Bone Marrow Transplantation 35:1201-1209.
38. Drouet M, Mourcin F, Grenier N, Leroux V, Denis J, Mayol JF, Thullier P, Lataillade JJ, Herodin F. 2004. Single administration of stem cell factor, FLT-3 ligand, megakaryocyte growth and development factor, and interleukin-3 in combination soon after irradiation prevents nonhuman primates from myelosuppression: Long-term follow-up of hematopoiesis. Blood 103:878-885.
39. Du XX, Doerschuk CM, Orazi A, Williams DA. 1994. A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 83:33-37.
40. Dumont F, Le Roux A, Bischoff P. 2010. Radiation countermeasure agents: An update. Expert Opinion on Therapeutic Patents 20:73-101.
41. Dunbar CE, Takatoku M, Donahue RE. 2001. The impact of ex vivo cytokine stimulation on engraftment of primitive hematopoietic cells in a non-human primate model. Annals of the New York Academy of Sciences 938:236-244; discussion 244-235.
42. Ege CA, Parra NC, Johnson TE. 2006. Noninfectious complications due to vascular access ports (VAPs) in Yucatan minipigs (Sus scrofa domestica). Journal of American Association for Laboratory Animal Science 45:27-34.
43. Fliedner TM, Friesecke I, Beyrer K. 2001. Medical Management of Radiation Accidents-Manual on the Acute Radiation Syndrome. Oxford, British Institute of Radiology.
44. Fliedner TM, Dorr DH, Meineke V. 2005. Multi-organ involvement as a pathogenetic principle of the radiation syndromes: A study involving 110 case histories documented in SEARCH and classified as the bases of haematopoietic indicators of effect. British Journal of Radiology Suppl. 27:1-8.
45. Foye WO. 1969. Radiation-protective agents in mammals. Journal of Pharmaceutical Sciences 58:283-300.
46. Foye WO. 1981. Radioprotective drugs. In: Wolff ME, editor. Burger's medicinal chemistry. New York: Wiley.
47. Fry TJ, Sinha M, Milliron M, Chu YW, Kapoor V, Gress RE, Thomas E, Mackall CL. 2004. Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution. Blood 104:2794-2800.
48. Ghosh SP, Kulkarni S, Hieber K, Toles R, Romanyukha L, Kao TC, Hauer-Jensen M, Kumar KS. 2009a. Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. International Journal of Radiation Biology 85:598-606.
49. Ghosh SP, Kulkarni S, Perkins MW, Gambles K, Hieber K, Maniar M, Seed T, Kumar KS. 2010. Recovery from radiation induced hematopoietic and gastrointestinal syndromes by Ex-Rad in murine model. 56th Annual Meeting of the Radiation Research Society. Maui, Hawaii, USA.
50. Ghosh SP, Perkins MW, Hieber K, Kulkarni S, Kao TC, Reddy EP, Reddy MV, Maniar M, Seed T, Kumar KS. 2009b. Radiation protection by a new chemical entity, Ex-Rad: Efficacy and mechanisms. Radiation Research 171:173-179.
51. Gianotti L, Alexander JW, Fukushima R, Pyles T. 1996. Steroid therapy can modulate gut barrier function, host defense, and survival in thermally injured mice. Journal of Surgical Research 62:53-58.
52. Gorin NC, Fliedner TM, Gourmelon P, Ganser A, Meineke V, Sirohi B, Powles R, Apperley J. 2006. Consensus conference on European preparedness for haematological and other medical management of mass radiation accidents. Annals of Hematology 85:671-679.
53. Gudkov AV, Komarova EA. 2003. The role of p53 in determining sensitivity to radiotherapy. Nature Reviews Cancer 3:117-129.
54. Hagiwara A, Nakayama F, Motomura K, Asada M, Suzuki M, Imamura T, Akashi M. 2009. Comparison of expression profiles of several fibroblast growth factor receptors in the mouse jejunum: Suggestive evidence for a differential radioprotective effect among major FGF family members and the potency of FGF1. Radiation Research 172:58-65.
55. Hall EJ, Giaccia AJ. 2006. Radiobiology for the radiobiologist. Philadelphia, PA: Lippincott Williams and Wilkins.
56. Harfouche G, Martin MT. 2010. Response of normal stem cells to ionizing radiation: A balance between homeostasis and genomic stability. Mutation Research 704:167-174.
57. Herodin F, Bourin P, Mayol JF, Lataillade JJ, Drouet M. 2003. Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma-irradiation promotes survival. Blood 101:2609-2616.
58. Herodin F, Drouet M. 2002. Autologous cell therapy as a new approach to treatment of radiation-induced bone marrow aplasia: Preliminary study in a baboon model. Canadian Journal of Physiology and Pharmacology 80:710-716.
59. Herodin F, Drouet M. 2005. Cytokine-based treatment of accidentally irradiated victims and new approaches. Experimental Hematology 33:1071-1080.
60. Herodin F, Grenier N, Drouet M. 2007a. Revisiting therapeutic strategies in radiation casualties. Experimental Hematology 35:28-33.
61. Herodin F, Roy L, Grenier N, Delaunay C, Bauge S, Vaurijoux A, Gregoire E, Martin C, Alonso A, Mayol JF, Drouet M. 2007b. Antiapoptotic cytokines in combination with pegfilgrastim soon after irradiation mitigates myelosuppression in nonhuman primates exposed to high irradiation dose. Experimental Hematology 35:1172-1181.
62. Herrmann T, Baumann M, Voigtmann L, Knorr A. 1997. Effect of irradiated volume on lung damage in pigs. Radiotherapy and Oncology 44:35-40.
63. Hertz CJ, Kiertscher SM, Godowski PJ, Bouis DA, Norgard MV, Roth MD, Modlin RL. 2001. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. Journal of Immunology 166:2444-2450.
64. Hill RP. 2005. Radiation effects on the respiratory system. British Journal of Radiology Suppl. 27:75-81.
65. Hopewell JW, Rezvani M, Moustafa HF. 2000. The pig as a model for the study of radiation effects on the lung. International Journal of Radiation Biology 76:447-452.
66. Hosseinimehr SJ. 2007. Trends in the development of radioprotective agents. Drug Discovery Today 12:794-805.
67. Hudak S, Leach MW, Xu Y, Menon S, Rennick D. 1998. Radioprotective effects of flk2/flt3 ligand. Experimental Hematology 26:515-522.
68. Humanetics. Available at: http://www.humaneticscorp.com/ Accessed 26 January 2011.
69. Jacobs A. 2006. Use of nontraditional animals for evaluation of pharmaceutical products. Expert Opinion on Drug Metabolism, Toxicology 2:345-349.
70. Kabelitz D. 2007. Expression and function of Toll-like receptors in T lymphocytes. Current Opinion in Immunology 19:39-45.
71. Kawai T, Akira S. 2006. TLR signaling. Cell Death and Differentiation 13:816-825.
72. Kolb HJ, Losslein LK, Beisser K, Schaffer E, Holler E, Schwella N, Hochhausser E, Lehmacher W, Balk O, Thierfelder S. 1990. Dose rate and fractionation of total body irradiation in dogs: Short and long term effects. Radiotherapy and Oncology 18(Suppl. 1):51-59.
73. Krivokrysenko V, Toshkov I, Gleiberman AS, Gudkov A, Feinstein E. 2009. Single injection of novel medical countermeasure CBLB502 rescues nonhuman primates within broad time window after lethal irradiation. 55th Annual Meeting of the Radiation Research Society. Savannah, GA, USA.
74. Krivokrysenko V, Toshov I, Gleiberman AS, Gudkov A, Feinstein E. 2010. Single injection of novel medical radiation countermeasure CBLB502 rescues nonhuman primates within broad time window after lethal irradiation. 56th Annual Meeting of the Radiation Research Society. Maui, Hawaii, USA.
75. Kulkarni S, Ghosh SP, Hauer-Jensen M, Kumar KS. 2010a. Hematological targets of radiation damage. Current Drug Targets 11:1375-1385.
76. Kulkarni S, Ghosh SP, Satyamitra M, Mog S, Hieber K, Romanyukha L, Gambles K, Toles R, Kao TC, Hauer-Jensen M, Kumar KS. 2010b. Gamma-tocotrienol protects hematopoietic stem and progenitor cells in mice after total-body irradiation. Radiation Research 173:738-747.
77. Kumar KS, Srinivasan V, Toles R, Jobe L, Seed TM. 2002. Nutritional approaches to radioprotection: Vitamin E. Military Medicine 167: 57-59.
78. Kumar R. 2010. Radioprotection and radiomitigation properties of Ex-Rad upon oral administration. 56th Annual Meeting of the Radiation Research Society. Maui, Hawaii, USA.
79. Landauer MR, Srinivasan V. 2009. Radioprotection by oral administration of genistein. In: Skpoek J, editor. Proceedings of the European Society of Radiation Biology. Bologna, Italy: Medimond Medical Publications.
80. Landauer MR, Srinivasan V, Seed TM. 2003. Genistein treatment protects mice from ionizing radiation injury. Journal of Applied Toxicology 23:379-385.
81. Li J, Shan Z, Ou G, Liu X, Zhang C, Baum BJ, Wang S. 2005. Structural and functional characteristics of irradiation damage to parotid glands in the miniature pig. International Journal of Radiation Oncology, Biology, Physics 62:1510-1516.
82. Li XH, Fu D, Latif NH, Mullaney CP, Ney PH, Mog SR, Whitnall MH, Srinivasan V, Xiao M. 2010. Delta-tocotrienol protects mouse and human hematopoietic progenitors from gamma-irradiation through extracellular signal-regulated kinase/mammalian target of rapamycin signaling. Haematologica 95:1996-2004.
83. Liu Q, Jiang B, Jiang LP, Wu Y, Wang XG, Zhao FL, Fu BH, Istvan T, Jiang E. 2008. Clinical report of three cases of acute radiation sickness from a (60)Co radiation accident in Henan Province in China. Journal of Radiation Research 49:63-69.
84. Loria RM, Conrad DH, Huff T, Carter H, Ben-Nathan D. 2000. Androstenetriol and androstenediol. Protection against lethal radiation and restoration of immunity after radiation injury. Annals of the New York Academy of Sciences 917:860-867.
85. Loria RM, Inge TH, Cook SS, Szakal AK, Regelson W. 1988. Protection against acute lethal viral infections with the native steroid dehydroepiandrosterone (DHEA). Journal of Medical Virology 26:301-314.
86. Loria RM, Padgett DA. 1992. Androstenediol regulates systemic resistance against lethal infections in mice. Archives of Virology 127: 103-115.
87. MacVittie TJ, Farese AM. 2002. Cytokine-based treatment for acute radiation-induced myelosuppression: Preclinical and clinical perspective. In: Ricks RC, Berger ME, O'Hara FM, editors. The medical basis for radiation-accident preparedness: The clinical care of victims. Boca Raton, FL: Parthenon.
88. MacVittie TJ, Farese AM. 2002. Cytokine-based treatment of radiation injury: Potential benefits after low-level radiation exposure. Military Medicine 167:68-70.
89. MacVittie TJ, Monroy RL, Patchen ML, Souza LM. 1990. Therapeutic use of recombinant human G-CSF (rhG-CSF) in a canine model of sublethal and lethal whole-body irradiation. International Journal of Radiation Biology 57:723-736.
90. Mahl JA, Vogel BE, Court M, Kolopp M, Roman D, Nogues V. 2006. The minipig in dermatotoxicology: Methods and challenges. Experimental and Toxicologic Pathology 57:341-345.
91. Maisin JR. 1998. Bacq and Alexander Award lecture - chemical radioprotection: Past, present, and future prospects. International Journal of Radiation Biology 73:443-450.
92. Maurya DK, Devasagayam TP, Nair CK. 2006. Some novel approaches for radioprotection and the beneficial effect of natural products. Indian Journal of Experimental Biology 44:93-114.
93. Meijne EI, van der Winden-van Groenewegen RJ, Ploemacher RE, Vos, O, David JA, Huiskamp R. 1991. The effects of x-irradiation on hematopoietic stem cell compartments in the mouse. Experimental Hematology 19:617-623.
94. Min D, Taylor PA, Panoskaltsis-Mortari A, Chung B, Danilenko DM, Farrell C, Lacey DL, Blazar BR, Weinberg KI. 2002. Protection from thymic epithelial cell injury by keratinocyte growth factor: A new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood 99:4592-4600.
95. Monig H, Messerschmidt O, Streffer C. 1990. Chemical radioprotection in mammals and in man. In: Scherer E, Streffer C, Trott KR, editors. Radiation exposure and occupational risks. Berlin: Springer.
96. Monroy RL, MacVittie TJ, Darden JH, Schwartz GN, Patchen ML. 1986. The rhesus monkey: A primate model for hemopoietic stem cell studies. Experimental Hematology 14:904-911.
97. Moroni M, Coolbaugh TV, Lombardini E, Mitchell JM, Moccia KD, Shelton LJ, Nagy V, Whitnall MH. 2011a. Hematopoietic radiation syndrome in the Gottingen minipig Radiation Research 176:89-101.
98. Moroni M, Coolbaugh TV, Mitchell JM, Lombardini E, Moccia KD, Shelton LJ, Nagy V, Whitnall MH. 2011b. Vascular access port implantation and serial blood sampling in a Gottingen minipig (Sus scrofa domestica) model of acute radiation injury. Journal of American Association for Laboratory Animal Science 50:65-72.
99. Moroni M, Lombardini E, Salber R, Kazemzedeh M, Nagy V, Olsen C, Whitnall MH. 2011c. Hematological changes as prognostic indicators of survival: Similarities between Gottingen minipigs, humans, and other large animal models. PLoS One 6:e25210.
100. Morris MD, Jones TD. 1989. Hematopoietic death of unprotected man from photon irradiations: Statistical modeling from animal experiments. International Journal of Radiation Biology 55:445-461.
101. Morrison RA, Zellmer DL, Dean RD. 1981. Low vs. high dose-rate effects on the acute reaction of pig skin to cobalt-60 gamma rays. International Journal of Radiation Oncology, Biology, Physics 7:359-364.
102. Motomura K, Hagiwara A, Komi-Kuramochi A, Hanyu Y, Honda E, Suzuki M, Kimura M, Oki J, Asada M, Sakaguchi N, Nakayama F, Akashi M, Imamura T. 2008. An FGF1:FGF2 chimeric growth factor exhibits universal FGF receptor specificity, enhanced stability and augmented activity useful for epithelial proliferation and radioprotection. Biochimica et Biophysica Acta 1780:1432-1440.
103. Moulder JE, Cohen EP. 2005. Radiation-induced multi-organ involvement and failure: The contribution of radiation effects on the renal system. British Journal of Radiology Suppl. 27:82-88.
104. Mouthon MA, Van der Meeren A, Gaugler MH, Visser TP, Squiban C, Gourmelon P, Wagemaker G. 1999. Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation. International Journal of Radiation Oncology, Biology, Physics 43:867-875.
105. Mouthon MA, Van der Meeren A, Vandamme M, Squiban C, Gaugler MH. 2002. Thrombopoietin protects mice from mortality and myelosuppression following high-dose irradiation: Importance of time scheduling. Canadian Journal of Physiology and Pharmacology 80:717-721.
106. Murray D. 1998. Aminothiols. In: Bump EA, Malaker K, editors. Radioprotectors: Chemical, biological and chemical perspective. Boca Raton, FL: CRC Press.
107. Muzio M, Bosisio D, Polentarutti N, D'Amico G, Stoppacciaro A, Mancinelli R, van't Veer C, Penton-Rol G, Ruco LP, Allavena P, Mantovani A. 2000. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: Selective expression of TLR3 in dendritic cells. Journal of Immunology 164:5998-6004.
108. Na Nakorn T, Traver D, Weissman IL, Akashi K. 2002. Myeloerythroid- restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. Journal of Clinical Investigation 109:1579-1585.
109. Nair CK, Parida DK, Nomura T. 2001. Radioprotectors in radiotherapy. Journal of Radiation Research 42:21-37.
110. Nair CK, Salvi V, Kagiya TV, Rajagopalan R. 2004. Relevance of radioprotectors in radiotherapy: Studies with tocopherol monoglucoside. Journal of Environmental Pathology, Toxicology and Oncology 23:153-160.
111. National Institute of Radiological Sciences Anzai K, Anzai K, Ueno M, Yakumaru H, Ueda J, Akashi M, Kobayashi S, Takata J, Ikota N. 2010. Radiation protection drug containing tocopherol or tocotrienol compound ester derivative as active ingredient, US 12/516722.
112. Neelis KJ, Dubbelman YD, Qingliang L, Thomas GR, Eaton DL, Wagemaker G. 1997. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. Experimental Hematology 25:1084-1093.
113. Neta R. 1997. Modulation of radiation damage by cytokines. Stem Cells 15(Suppl. 2):87-94.
114. Neumedicines. Available at: http:/www.neumedicines.com/about.shtml. Accessed February 2011.
115. Nothdurft W, Fliedner TM, Fritz TE, Seed TM. 1995. Response of hemopoiesis in dogs to continuous low dose rate total body irradiation. Stem Cells 13(Suppl. 1):261-267.
116. Okunieff P, Mester M, Wang J, Maddox T, Gong X, Tang D, Coffee M, Ding I. 1998. In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice. Radiation Research 150:204-211.
117. Onconova Therapeutics, I. Available at: http://www.onconova.com/. Accessed 28 January 2011.
118. Orschell CM, Plett A, Yamin M, Brines M, Katz B, Juliar B, Farese A, MacVittie TM, Booth C. 2009. AR290 is an efficacious radiomitigator of both the hematopoietic and gastrointestinal syndromes of the acute radiation syndrome. 55th Annual Meeting of the Radiation Research Society. Savannah, GA, USA.
119. Ostby I, Kvalheim G, Rusten LS, Grottum P. 2004. Mathematical modeling of granulocyte reconstitution after high-dose chemotherapy with stem cell support: Effect of post-transplant G-CSF treatment. Journal of Theoretical Biology 231:69-83.
120. Padgett DA, Loria RM, Sheridan JF. 1997. Endocrine regulation of the immune response to influenza virus infection with a metabolite of DHEA-androstenediol. Journal of Neuroimmunology 78:203-211.
121. Padgett DA, MacCallum RC, Loria RM, Sheridan JF. 2000. Androstenediol-induced restoration of responsiveness to influenza vaccination in mice. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 55:B418-424.
122. Patchen ML, MacVittie TJ, Solberg BD, Souza LM. 1990. Therapeutic administration of recombinant human granulocyte colony-stimulating factor accelerates hemopoietic regeneration and enhances survival in a murine model of radiation-induced myelosuppression. International Journal of Cell Cloning 8:107-122.
123. Pellmar TC, Rockwell S. 2005. Priority list of research areas for radiological nuclear threat countermeasures. Radiation Research 163:115-123.
124. Pihl A, Eldjarn L. 1958. Pharmacological aspects of ionizing radiation and of chemical protection in mammals. Pharmacological Reviews 10:437-474.
125. Ploemacher RE, van Os R, van Beurden CA, Down JD. 1992. Murine haemopoietic stem cells with long-term engraftment and marrow repopulating ability are more resistant to gamma-radiation than are spleen colony forming cells. International Journal of Radiation Biology 61:489-499.
126. Potten CS, Booth D, Cragg NJ, Tudor GL, O'Shea JA, Booth C, Meineke FA, Barthel D, Loeffler M. 2002. Cell kinetic studies in the murine ventral tongue epithelium: Mucositis induced by radiation and its protection by pretreatment with keratinocyte growth factor (KGF). Cell Proliferation 35(Suppl. 1):32-47.
127. Radfar L, Sirois DA. 2003. Structural and functional injury in minipig salivary glands following fractionated exposure to 70 Gy of ionizing radiation: An animal model for human radiation-induced salivary gland injury. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics 96:267-274.
128. Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG. 2006. Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 6:107.
129. Rharbaoui F, Drabner B, Borsutzky S, Winckler U, Morr M, Ensoli B, Muhlradt PF, Guzman CA. 2002. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. European Journal of Immunology 32:2857-2865.
130. Robbins ME, Campling D, Rezvani M, Golding SJ, Hopewell JW. 1989. Radiation nephropathy in mature pigs following the irradiation of both kidneys. International Journal of Radiation Biology 56:83-98.
131. Salazar JC, Pope CD, Sellati TJ, Feder HM Jr, Kiely TG, Dardick KR, Buckman RL, Moore MW, Caimano MJ, Pope JG, Krause PJ, Radolf JD. 2003. Coevolution of markers of innate and adaptive immunity in skin and peripheral blood of patients with erythema migrans. Journal of Immunology 171:2660-2670.
132. Satyamitra M, Kulkarni S, Ghosh SP, Mullaney C, Condliffe D, Srinivasan V. 2011a. Hematopoietic recovey and amelioration of radiation-induced lethality by the vitamin E isoform, deltatocotrienol. Radiation Research 175:736-745.
133. Satyamitra M, Lombardini E, Graves J III, Mullaney C, Ney P, Hunter A, Jhonson P, Tamburini Y, Wang J, Springhorn J, Srinivasan V. 2011b. A TPO receptor agonist, ALXN4100TPO, mitigates radiation-induced lethality and stimulates hematopoiesis in CD2F1 mice. Radiation Research 175:746-758.
134. Shibata K, Hasebe A, Into T, Yamada M, Watanabe T. 2000. The N-terminal lipopeptide of a 44-kDa membrane-bound lipoprotein of Mycoplasma salivarium is responsible for the expression of intercellular adhesion molecule-1 on the cell surface of normal human gingival fibroblasts. Journal of Immunology 165:6538-6544.
135. Singh PK, Wise SY, Ducey EJ, Brown DS, Singh VK. 2011a. Radioprotective efficacy of tocopherol succinate is mediated through granulocyte-colony stimulating factor. Cytokine 56:411-421.
136. Singh PK, Wise SY, Ducey EJ, Fatanmi OO, Elliott TB, Singh VK. 2012. α-Tocopherol succinate protects mice against radiation-induced gastrointestinal injury. Radiation Research 177:133-145.
137. Singh VK, Brown DS, Fatanmi OO, Parekh VI, Gille DA, Whitnall MH, Christensen JL. 2009a. Myeloid progenitor cells as an effective treatment for acute radiation syndrome. 55th Annual Meeting of the Radiation Research Society. Savannah, GA, USA.
138. Singh VK, Brown DS, Kao TC. 2009b. Tocopherol succinate: A promising radiation countermeasure. International Immunopharmacology 9:1423-1430.
139. Singh VK, Brown DS, Kao TC. 2010a. Alpha-tocopherol succinate protects mice from gamma-radiation by induction of granulocytecolony stimulating factor. International Journal of Radiation Biology 86:12-21.
140. Singh VK, Brown DS, Kao TC, Seed TM. 2010b. Preclinical development of a bridging therapy for radiation casualties. Experimental Hematology 38:61-70.
141. Singh VK, Ducey EJ, Fatanmi OO, Singh PK, Brown DS, Purmal A, Shakhov VV, Gudkov A, Feinstein E. 2011c. CBLB613: A TLR 2/6 agonist, natural lipopeptide of Mycoplasma arginini , as a novel radiation countermeasure. Radiation Research (in press).
142. Singh VK, Grace MB, Parekh VI, Whitnall MH, Landauer MR. 2009c. Effects of genistein administration on cytokine induction in wholebody gamma irradiated mice. International Immunopharmacology 9:1401-1410.
143. Singh VK, Kehl ML, Bone F, Feinstein E, Shakhov A. 2008a. Cytokine profile induced by a potential radiation countermeasure: A novel synthetic lipopeptide, CBLB612. Uniformed Services University of the Health Sciences Research Day. Bethesda, MD, USA.
144. Singh VK, Krivokrysenko V, Shakhov A, Bone F, Whitnall MH, Pellmar TC, Feinstein E. 2008b. Cytokines as biomarkers for radiation countermeasures. 54th Annual Meeting of the Radiation Research Society. Boston, MA, USA.
145. Singh VK, Parekh VI, Brown DS, Kao TC, Mog SR. 2011d. Tocopherol succinate: Modulation of antioxidant enzymes and oncogene expression, and hematopoietic recovery. International Journal of Radiation Oncology, Biology, Physics 79:571-578.
146. Singh VK, Shafran RL, Inal CE, Jackson WE III, Whitnall MH. 2005. Effects of whole-body gamma irradiation and 5-androstenediol administration on serum G-CSF. Immunopharmacology and Immunotoxicology 27:521-534.
147. Singh VK, Shafran RL, Jackson WE III, Seed TM, Kumar KS. 2006. Induction of cytokines by radioprotective tocopherol analogs. Experimental and Molecular Pathology 81:55-61.
148. Srinivasan V, Weiss JF. 1992. Radioprotection by vitamin E: Injectable vitamin E administered alone or with WR-3689 enhances survival of irradiated mice. International Journal of Radiation Oncology, Biology, Physics 23:841-845.
149. Stickney DR, Dowding C, Authier S, Garsd A, Onizuka-Handa N, Reading C, Frincke JM. 2007. 5-androstenediol improves survival in clinically unsupported rhesus monkeys with radiation-induced myelosuppression. International Immunopharmacology 7:500-505.
150. Stickney DR, Dowding C, Garsd A, Ahlem C, Whitnall M, McKeon M, Reading C, Frincke J. 2006. 5-androstenediol stimulates multilineage hematopoiesis in rhesus monkeys with radiation-induced myelosuppression. International Immunopharmacology 6:1706-1713.
151. Stickney DR, Groothuis JR, Ahlem C, Kennedy M, Miller BS, Onizuka-Handa N, Schlangen KM, Destiche D, Reading C, Garsd A, Frincke JM. 2010. Preliminary clinical findings on NEUMUNE as a potential treatment for acute radiation
152. Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff MH, Dynan WS, Fike JR, Grdina DJ, Greenberger JS, Hauer-Jensen M, Hill RP, Kolesnick RN, MacVittie TJ, Marks C, McBride WH, Metting N, Pellmar T, Purucker M, Robbins ME, Schiestl RH, Seed TM, Tomaszewski JE, Travis EL, Wallner PE, Wolpert M, Zaharevitz D. 2004. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiation Research 162:711-728.
153. Suitters AJ, Shaw S, Wales MR, Porter JP, Leonard J, Woodger R, Brand H, Bodmer M, Foulkes R. 1997. Immune enhancing effects of dehydroepiandrosterone and dehydroepiandrosterone sulphate and the role of steroid sulphatase. Immunology 91:314-321.
154. Tanikawa S, Nose M, Aoki Y, Tsuneoka K, Shikita M, Nara N. 1990. Effects of recombinant human granulocyte colony-stimulating factor on the hematologic recovery and survival of irradiated mice. Blood 76:445-449.
155. Uma Devi P. 2001. Radioprotective, anticarcinogenic and antioxidant properties of the Indian holy basil, Ocimum sanctum (Tulasi). Indian Journal of Experimental Biology 39:185-190.
156. Uma Devi P, Ganasoundari A, Rao BS, Srinivasan KK. 1999. In vivo radioprotection by ocimum flavonoids: Survival of mice. Radiation Research 151:74-78.
157. Uma Devi P, Ganasoundari A, Vrinda B, Srinivasan KK, Unnikrishnan MK. 2000. Radiation protection by the ocimum flavonoids orientin and vicenin: Mechanisms of action. Radiation Research 154:455-460.
158. Uma Devi P, Satyamitra M. 2004. Protection against prenatal irradiation-induced genomic instability and its consequences in adult mice by ocimum flavonoids, orientin and vicenin. International Journal of Radiation Biology 80:653-662.
159. US Department of Defense. 2010. 2010 Department of Defense Chemical and Biological Defense Program. Available at: http://www.jpeocbd.osd.mil/packs/ DocHandler.ashx?DocID=11104.
160. US Secretary Department of Health and Human Services Uniformed Services University of the Health Sciences, Landauer MR, Seed TM, Srinivasan V, Shapiro A, Takimoto CH. Isoflavones against radiation-induced mortality. EP1767215, 2007.
161. Valachovicova T, Slivova V, Bergman H, Shuherk J, Sliva D. 2004. Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-kappaB/AP-1-dependent and -independent pathways. International Journal of Oncology 25:1389-1395.
162. van der Laan JW, Brightwell J, McAnulty P, Ratky J, Stark C. 2010. Regulatory acceptability of the minipig in the development of pharmaceuticals, chemicals and other products. Journal of Pharmacological and Toxicological Methods 62:184-195.
163. Vijay-Kumar M, Aitken JD, Sanders CJ, Frias A, Sloane VM, Xu J, Neish AS, Rojas M, Gewirtz AT. 2008. Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. Journal of Immunology 180:8280-8285.
164. von Zallinger C, Tempel K. 1998. The physiologic response of domestic animals to ionizing radiation: A review. Veterinary Radiology and Ultrasound 39:495-503.
165. Wang S, Liu Y, Fang D, Shi S. 2007. The miniature pig: A useful large animal model for dental and orofacial research. Oral Diseases 13:530-537.
166. Waselenko JK, MacVittie TJ, Blakely WF, Pesik N, Wiley AL, Dickerson WE, Tsu H, Confer DL, Coleman CN, Seed T, Lowry P, Armitage JO, Dainiak N. 2004. Medical management of the acute radiation syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group. Annals of Internal Medicine 140:1037-1051.
167. Wasserman, TH & Brizel, DM. 2001. The role of amifostine as a radioprotector. Oncology (Williston Park) 15:1349-1354; discussion 1357-1360.
168. Weiss JF. 1997. Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environmental Health Perspectives 105(Suppl. 6):1473-1478.
169. Weiss JF, Kumar KS, Walden TL, Neta R, Landauer MR, Clark EP. 1990. Advances in radioprotection through the use of combined agent regimens. International Journal of Radiation Biology 57:709-722.
170. Weiss JF, Landauer MR. 2000. Radioprotection by antioxidants. Annals of the New York Academy of Sciences 899:44-60.
171. Weiss JF, Landauer MR. 2003. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology 189:1-20.
172. Weiss JF, Landauer MR. 2009. History and development of radiation-protective agents. International Journal of Radiation Biology 85:539-573.
173. Whitnall MH, Elliott TB, Harding RA, Inal CE, Landauer MR, Wilhelmsen CL, McKinney L, Miner VL, Jackson WE III, Loria RM, Ledney GD, Seed TM. 2000. Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice. International Journal of Immunopharmacology 22:1-14.
174. Whitnall MH, Inal CE, Jackson WE III, Miner VL, Villa V, Seed TM. 2001. In vivo radioprotection by 5-androstenediol: Stimulation of the innate immune system. Radiation Research 156:283-293.
175. Whitnall MH, Villa V, Seed TM, Benjack J, Miner V, Lewbart ML, Dowding CA, Jackson WE III. 2005. Molecular specificity of 5-androstenediol as a systemic radioprotectant in mice. Immunopharmacology and Immunotoxicology 27:1-18.
176. Whitnall MH, Wilhelmsen CL, McKinney L, Miner V, Seed TM, Jackson WE III. 2002. Radioprotective efficacy and acute toxicity of 5-androstenediol after subcutaneous or oral administration in mice. Immunopharmacology and Immunotoxicology 24:595-626.
177. Williams JP, Brown SL, Georges GE, Hauer-Jensen M, Hill RP, Huser AK, Kirsch DG, MacVittie TJ, Mason KA, Medhora MM, Moulder JE, Okunieff P, Otterson MF, Robbins ME, Smathers JB, McBride WH. 2010. Animal models for medical countermeasures to radiation exposure. Radiation Research 173:557-578.
178. Wingard JR, Dainiak N. 2010. Treatment of radiation injury in the adult. Up-to-date, version 17.2. Available at: http://www.uptodate.com. Accessed March 2010.
179. Xiao M, Inal CE, Parekh VI, Chang CM, Whitnall MH. 2007. 5-Androstenediol promotes survival of gamma-irradiated human hematopoietic progenitors through induction of nuclear factor-kappaB activation and granulocyte colony-stimulating factor expression. Molecular Pharmacology 72:370-379.
180. Xiao M, Whitnall MH. 2009. Pharmacological countermeasures for the acute radiation syndrome. Current Molecular Pharmacology 2:122-133.
181. Yashar CM, Spanos WJ, Taylor DD, Gercel-Taylor C. 2005. Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecologic Oncology 99:199-205.
182. Yoon J. 2010. Cellerant Therapeutics awarded $ 153 million contract by Biomedical Advanced Research and Development Authority (BARDA) to develop treatment for acute radiation syndrome (ARS). Available at: http://www.cellerant.com/pr-090110.html.
183. Zenk JL. 2007. New therapy for the prevention and prophylactic treatment of acute radiation syndrome. Expert Opinion on Investigational Drugs 16:767-770.
184. Zhou Y, Mi MT. 2005. Genistein stimulates hematopoiesis and increases survival in irradiated mice. Journal of Radiation Research 46:425-433.
185. Zsebo KM, Smith KA, Hartley CA, Greenblatt M, Cooke K, Rich W, McNiece IK. 1992. Radioprotection of mice by recombinant rat stem cell factor. Proceedings of the National Academy of Sciences of the USA 89:9464-9468.